Europe
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.
BioArctic AB comments on the decision by Nasdaq Stockholm to halt trading in BioArctic due to large movements in the share price.
GHP Announces the Manufacturing and Packaging Awards 2019 Winners
Genedata Biologics® streamlines Teva’s R&D workflows and increases operational efficiency
Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II
AdrenOSS-II trial continues as planned after positive interim efficacy analysis triggered by the treatment of 50% of randomized patients
First hospital outside of Germany to offer MagForce’s NanoTherm therapy for the commercial treatment of brain tumor patients
AZP-3404, an optimized peptide derived from IGFBP-2, improves glucose control in a preclinical model of severe insulin resistance through a new and unique mechanism of action
People with Alzheimer’s disease using antiepileptic drugs have twice the risk of pneumonia compared to non-users, a new study from the University of Eastern Finland shows.
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2018 and its outlook for 2019.
PRESS RELEASES